Constipation is a gastrointestinal condition characterized by infrequent bowel movements, hard stools, or difficulty passing stools, often associated with dietary, behavioral, or medical factors.
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
The FDA approved Tecvayli plus Darzalex Faspro for relapsed/refractory multiple myeloma in March 2026, and Darzalex Faspro-based quadruplet D-VRd for newly diagnosed transplant-ineligible patients in January 2026.
The FDA approved pembrolizumab in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1).
Microdosing GLP-1 medications like Ozempic and Wegovy has emerged as a weight-loss trend, but health experts warn there is no scientific data supporting the practice and caution about potential safety risks.
GLP-1 weight loss drugs show increasing efficacy but raise concerns about excessive weight loss, side effects, and the rise of unregulated compounded versions sold online.
Clinical studies demonstrate GLP-1 receptor agonists like semaglutide and tirzepatide produce substantial weight loss when combined with lifestyle changes, with patients achieving mean reductions of 14.9% body weight over 68 weeks.
The FDA announced plans to restrict non-FDA-approved compounded GLP-1 drugs mass-marketed as alternatives to approved weight loss medications, citing safety concerns and misleading advertising practices.
The FDA approved pembrolizumab (Keytruda) and Keytruda Qlex plus paclitaxel, with or without bevacizumab, for adults with PD-L1+ platinum-resistant ovarian carcinoma based on Phase 3 trial data showing improved survival outcomes.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07570004 |
The Effect of Preoperative Abdominal Massage on Postoperative Constipation |
COMPLETED | NA |
| NCT07545772 |
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) |
RECRUITING | PHASE2 |
| NCT07529457 |
Akk09 in Adults With Constipation |
NOT_YET_RECRUITING | NA |
| NCT07522255 |
Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders |
NOT_YET_RECRUITING | PHASE3 |
| NCT07470892 |
Preoperative Fish Oil PN and Prognosis After Constipation Surgery |
NOT_YET_RECRUITING | |
| NCT07466914 |
Constipation in Children With Cerebral Palsy |
ACTIVE_NOT_RECRUITING | |
| NCT07462481 |
Probiotic Improve Constipation |
RECRUITING | NA |
| NCT07444008 |
Randomized, Blinded, Placebo-Controlled Evaluation of BioAmicus Complete |
RECRUITING | NA |
| NCT07410286 |
Comparative Research Between Swenson and Soave Operations for Pediatric Patients Who Have Hirschsprung Disease |
COMPLETED | NA |
| NCT07402785 |
The Effect of Abdominal Massage on Constipation |
COMPLETED | NA |
